A Czech biotech bets big on ris­ing ADC play­er LegoChem as part of li­cens­ing pact aimed at sol­id tu­mors

Czech biotech So­tio will pay $29.5 mil­lion up­front and in near-term mile­stones with a po­ten­tial $1.03 bil­lion in down­stream biobucks to li­cense five an­ti­body-drug con­ju­gate pro­grams from LegoChem Bio­sciences, the part­ners an­nounced Tues­day.

De­tails on the col­lab­o­ra­tion are slim, but So­tio did say the pro­grams would tar­get dis­tinct anti­gens in sol­id tu­mors. The pact will lever­age So­tio’s an­ti­body li­brary with LegoChem’s pay­load-link­er tech­nol­o­gy in what the part­ners hope will prove a po­tent com­bi­na­tion against can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER